DNB Asset Management Increases Stake in Vertex Pharmaceuticals

Institutional investor boosts holdings in biotech firm by nearly 10%

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

DNB Asset Management AS, a Norwegian investment management firm, increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.8% in the third quarter, according to a recent SEC filing. The firm now owns 95,414 shares of the pharmaceutical company's stock, valued at $37.4 million.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing treatments for serious diseases, particularly cystic fibrosis. The increase in DNB Asset Management's stake suggests continued investor confidence in the company's pipeline and long-term growth prospects.

The details

According to the filing, DNB Asset Management bought an additional 8,483 shares of Vertex Pharmaceuticals during the third quarter, bringing its total holdings to 95,414 shares. The investment firm's increased stake in Vertex comes as the company continues to make progress on its pipeline of CFTR modulators and other therapies.

  • DNB Asset Management increased its Vertex Pharmaceuticals holdings in the 3rd quarter of 2025.

The players

DNB Asset Management AS

A Norwegian investment management firm that has increased its stake in Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

The increase in DNB Asset Management's stake in Vertex Pharmaceuticals suggests continued institutional investor confidence in the biotech firm's long-term growth potential as it advances its pipeline of innovative treatments.